MX9304611A - Clohidrato de triazoliltiometiltio cefalosporina, su hidrato cristalino y proceso para su preparacion. - Google Patents

Clohidrato de triazoliltiometiltio cefalosporina, su hidrato cristalino y proceso para su preparacion.

Info

Publication number
MX9304611A
MX9304611A MX9304611A MX9304611A MX9304611A MX 9304611 A MX9304611 A MX 9304611A MX 9304611 A MX9304611 A MX 9304611A MX 9304611 A MX9304611 A MX 9304611A MX 9304611 A MX9304611 A MX 9304611A
Authority
MX
Mexico
Prior art keywords
crystalline hydrate
triazolyltiomethyl
clohydrate
cephalosporine
preparation
Prior art date
Application number
MX9304611A
Other languages
English (en)
Inventor
Hisanori Takahashi
Yutaka Ide
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co filed Critical Shionogi & Co
Publication of MX9304611A publication Critical patent/MX9304611A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cephalosporin Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describe el clorhidrato del ácido 7-beta-[(Z)-(2-amino-4-tiazolil)-2-hidroxiiminoace tamino]-3-cefem-4-carboxílico y su hidrato cristalino, los cuales tienen una potente actividad antibiótica y son de baja toxicidad y farmacéuticamente estables, con lo cual son útiles como ingredientes activo de formulaciones antibióticas clínicamente útiles, y la producción de los mismos.
MX9304611A 1992-07-31 1993-07-30 Clohidrato de triazoliltiometiltio cefalosporina, su hidrato cristalino y proceso para su preparacion. MX9304611A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP20496592 1992-07-31

Publications (1)

Publication Number Publication Date
MX9304611A true MX9304611A (es) 1994-02-28

Family

ID=16499234

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9304611A MX9304611A (es) 1992-07-31 1993-07-30 Clohidrato de triazoliltiometiltio cefalosporina, su hidrato cristalino y proceso para su preparacion.

Country Status (23)

Country Link
US (1) US5407929A (es)
EP (1) EP0581552B1 (es)
KR (1) KR100245938B1 (es)
CN (1) CN1037683C (es)
AT (1) ATE165360T1 (es)
AU (1) AU657866B2 (es)
BR (1) BR9303235A (es)
CA (1) CA2101502A1 (es)
DE (1) DE69318077T2 (es)
ES (1) ES2115725T3 (es)
FI (1) FI933391A7 (es)
GR (1) GR3026699T3 (es)
HU (1) HU219637B (es)
IL (1) IL106516A (es)
MX (1) MX9304611A (es)
NO (1) NO303734B1 (es)
NZ (1) NZ248285A (es)
PH (1) PH30109A (es)
PL (2) PL172830B1 (es)
RU (1) RU2118959C1 (es)
TW (1) TW307769B (es)
UA (1) UA37181C2 (es)
ZA (1) ZA935529B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ528216A (en) * 2001-02-24 2006-12-22 Boehringer Ingelheim Pharma Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
AT413282B (de) * 2002-02-01 2006-01-15 Sandoz Ag Kristalline salze der 7-(((5-amino-1,2,4-thiadiazol-3-yl) (fluoromethoxy-imino)acetyl)amino)-3- ((imino-1-piperazinylmethyl)
KR20030076759A (ko) * 2002-03-21 2003-09-29 주식회사 엘지생명과학 신규 세팔로스포린 화합물 및 그의 제조 방법
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US6727277B1 (en) 2002-11-12 2004-04-27 Kansas State University Research Foundation Compounds affecting cholesterol absorption
CN101219992B (zh) 2003-02-12 2011-08-31 日产化学工业株式会社 匹伐他汀钙的晶形
DE602004022643D1 (de) 2003-03-27 2009-10-01 Basilea Pharmaceutica Ag Cephalosporin in kristalliner form
US7501426B2 (en) * 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
PE20080251A1 (es) * 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
NZ573360A (en) * 2006-05-04 2012-08-31 Boehringer Ingelheim Int Polymorphic forms of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine
RU2569749C2 (ru) * 2007-08-17 2015-11-27 Бёрингер Ингельхайм Интернациональ Гмбх Производные пурина, предназначенные для применения для лечения заболеваний, связанных с баф (белок-активатор фибробластов)
PE20140960A1 (es) * 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
EA031225B1 (ru) * 2008-08-15 2018-12-28 Бёрингер Ингельхайм Интернациональ Гмбх Ингибиторы дпп-4 для заживления ран
AU2009290911A1 (en) 2008-09-10 2010-03-18 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
MX2011006713A (es) 2008-12-23 2011-07-13 Boehringer Ingelheim Int Formas salinas de compuesto organico.
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
AU2010323068B2 (en) 2009-11-27 2015-09-03 Boehringer Ingelheim International Gmbh Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin
KR101927068B1 (ko) 2010-05-05 2018-12-10 베링거 인겔하임 인터내셔날 게엠베하 체중 감소 치료에 후속하는 dpp-4 억제제에 의한 순차적 병용 요법
WO2011161161A1 (en) 2010-06-24 2011-12-29 Boehringer Ingelheim International Gmbh Diabetes therapy
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
WO2013010964A1 (en) 2011-07-15 2013-01-24 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP2849754B1 (en) 2012-05-14 2022-09-14 Boehringer Ingelheim International GmbH Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis
EP2849755A1 (en) 2012-05-14 2015-03-25 Boehringer Ingelheim International GmbH A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
ES2950384T3 (es) 2014-02-28 2023-10-09 Boehringer Ingelheim Int Uso médico de un inhibidor de DPP-4
JP2019517542A (ja) 2016-06-10 2019-06-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング リナグリプチンおよびメトホルミンの組合せ

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES475573A1 (es) * 1977-07-12 1980-01-16 Fujisawa Pharmaceutical Co Un procedimiento para preparar nuevos compuestos de cefem
IE65926B1 (en) * 1990-07-19 1995-11-29 Shionogi & Co Thioalkylthio cephalosporin derivatives

Also Published As

Publication number Publication date
CN1089948A (zh) 1994-07-27
RU2118959C1 (ru) 1998-09-20
CN1037683C (zh) 1998-03-11
UA37181C2 (uk) 2001-05-15
PL299870A1 (en) 1994-02-07
TW307769B (es) 1997-06-11
US5407929A (en) 1995-04-18
IL106516A0 (en) 1993-11-15
NO932745D0 (no) 1993-07-30
CA2101502A1 (en) 1994-02-01
PL172835B1 (pl) 1997-12-31
HU9302194D0 (en) 1993-10-28
FI933391L (fi) 1994-02-01
EP0581552A2 (en) 1994-02-02
NZ248285A (en) 1994-07-26
NO303734B1 (no) 1998-08-24
BR9303235A (pt) 1994-03-01
DE69318077T2 (de) 1998-10-29
HU219637B (hu) 2001-06-28
KR940005636A (ko) 1994-03-22
FI933391A0 (fi) 1993-07-29
ZA935529B (en) 1994-02-24
ATE165360T1 (de) 1998-05-15
PL172830B1 (pl) 1997-12-31
KR100245938B1 (ko) 2000-04-01
PH30109A (en) 1996-12-27
AU657866B2 (en) 1995-03-23
NO932745L (no) 1994-02-01
ES2115725T3 (es) 1998-07-01
DE69318077D1 (de) 1998-05-28
EP0581552A3 (en) 1994-06-01
HUT68602A (en) 1995-06-28
GR3026699T3 (en) 1998-07-31
FI933391A7 (fi) 1994-02-01
AU4422793A (en) 1994-02-03
IL106516A (en) 1998-06-15
EP0581552B1 (en) 1998-04-22

Similar Documents

Publication Publication Date Title
MX9304611A (es) Clohidrato de triazoliltiometiltio cefalosporina, su hidrato cristalino y proceso para su preparacion.
PT91246A (pt) Processo para a preparacao de composicoes farmaceuticas para administracao endovenosa, contendo ciclosporina como ingrediente activo
BR0009176A (pt) Partìcula granular, forma de dosagem, métodopara preparar uma partìcula granular, misturaseca, e, formulação granular
MY120842A (en) 1,4-benzothiazepine-1, 1-dioxide derivatives substituted by sugar residues, process for their preparation, pharmaceuticals comprising these compounds, and their use.
AR028833A1 (es) Compuestos inhibidores de metaloproteasas, composiciones farmaceuticas, uso para la manufactura de medicamentos, metodo de tratamiento y procedimiento para su preparacion
IT1201149B (it) Complessi di bioflavonoidi con fosfolipidi,loro preparazione,uso e composizioni farmaceutici e cosmetiche
HN2004000232A (es) " derivados de pirrolo(3,4-c) pirazol activos como inhibidores de quinasa, proceso para su preparacion y composiciones farmaceuticas que los comprenden."
MEP10408A (en) Platinum derivative pharmaceutical formulations
CA2098076A1 (en) Imidate prodrugs of pharmaceutically useful anticonvulsant sulfamates
TR200100894T2 (tr) Aril ikameli propanolamin türevleri, imalat yöntemleri, ilaç maddeleri, kullanımları.
NO20035210L (no) 2-anilino-pyrimidinderivater som cyklinavhengige kinaseinhibitorer
EP0937459A3 (en) Pharmaceutical compositions for the treatment of ischemic brain damage
BR0313162A (pt) Composto, processo para preparar o mesmo, e, composição farmacêutica
AR026064A1 (es) Compuestos de oxabispidina, formulacion farmaceutica, uso de estos compuestos para la manufactura de medicamentos, proceso para la preparacion de estos compuestos, e intermediarios.
ES2054949T3 (es) Precursores de dopamina.
IT1263089B (it) Composti pirrol-amidinici, processi di preparazione e composizioni farmaceutiche che li contengono.
IT1271456B (it) Composti pirrol-amidinici, e loro sali farmaceuticamente accettabili, processi di preparazione e composizioni farmaceutiche che li contengono
JP2000159790A5 (es)
ES2057225T3 (es) Una composicion para la preparacion de una vitamina d3 activa en forma de dosificacion y su procedimiento de preparacion.
DE60233276D1 (de) Verfahren zur Herstellung der Natrium Salze von Retinoylderivaten
AR021086A1 (es) Omega-amidas de n-arilsulfonil-aminoacidos, un procedimiento para su preparacion, medicamento, uso de dichos compuestos para la preparacion de un medicamento y procedimiento para la preparacion de un medicamento.
ES8605532A1 (es) Un procedimiento para preparar derivados de aminoglicosido
HUT50334A (en) Process for producing arylpiperazinyl-alkilenephenyl-p-heterocycluc compounds, pharmaceutically acceptable acid addition salts thereof and pharmaceutical compositions comprising the compounds as active ingredient
HUP0600084A2 (en) Pharmaceutical compositions containing ascorbic acid derivatives, methods of production of the active ingredient
IE37250B1 (en) Diazepine derivatives and processes for their production